|
Synonyms: BYM-338 | BYM338
Compound class:
Antibody
Comment: Bimagrumab is an investigational monoclonal antibody that binds to activin type II A and B receptors to block activin and myostatin signalling in muscles and adipose tissue. It was originally intended to combat age-related muscle loss and other muscle-wasting conditions. Most recently it has been repositioned as a counter measure for the muscle loss in patients using GLP-1 agonist anti-obesity drugs such as semaglutide and tirzepatide.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Berger C, Herrmann T, Lu C, Sheppard K-A, Trifilieff E, Urlinger S. (2013)
Compositions and methods for increasing muscle growth. Patent number: US8388968. Assignee: Novartis Ag. Priority date: 27/04/2009. Publication date: 05/03/2013. |
|
2. Bogdanovich S, McNally EM, Khurana TS. (2008)
Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C. Muscle Nerve, 37 (3): 308-16. [PMID:18041051] |
|
3. Han HQ, Zhou X, Mitch WE, Goldberg AL. (2013)
Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol, 45 (10): 2333-47. [PMID:23721881] |
|
4. Hanna MG, Badrising UA, Benveniste O, Lloyd TE, Needham M, Chinoy H, Aoki M, Machado PM, Liang C, Reardon KA et al.. (2019)
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol, 18 (9): 834-844. [PMID:31397289] |
|
5. Hofbauer LC, Witvrouw R, Varga Z, Shiota N, Cremer M, Tanko LB, Rooks D, Auberson LZ, Arkuszewski M, Fretault N et al.. (2021)
Bimagrumab to improve recovery after hip fracture in older adults: a multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a/b trial. Lancet Healthy Longev, 2 (5): e263-e274. [PMID:36098133] |
|
6. Rooks D, Swan T, Goswami B, Filosa LA, Bunte O, Panchaud N, Coleman LA, Miller RR, Garcia Garayoa E, Praestgaard J et al.. (2020)
Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial. JAMA Netw Open, 3 (10): e2020836. [PMID:33074327] |
